Floatz logo

Alirocumab

Cerebral Atherosclerosis

Chang Gung Memorial Hospitalmonoclonal_antibodyPhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Cerebral Atherosclerosis cohort.

Asset / SponsorPhaseRating
Ferumoxytol
Northwestern University
Phase 4BB
Atorvastatin
General Hospital of Shenyang Military Region
Phase 4BB
Probucol
General Hospital of Shenyang Military Region
Phase 4BB
Rucacuzumab
Peking Union Medical College Hospital
Phase 4BB
Immunoglobulin G1 (256-Tyrosine,258-Threonine,260-Glutamic Acid), Anti-(Neural Apoptosis-Regulated Proteinase 1) (Human-Mus Musculus Monoclonal Hrp00130 .Gamma.1-Chain), Disulfide With (3-Valine,5-Serine,49-Serine,66-Aspartic Acid) Human-Mus Musculus Monoclonal Hrp00130 .Kappa.-Chain, Dimer
Peking Union Medical College Hospital
Phase 4BB

View all 12 →

Same molecule, other indications

Alirocumab is also rated in:

inherited lipid metabolism disorderDormant
BB
Indicative · Phase 3
66 / 100
View asset →
acute coronary syndromeDormant
BB
Indicative · Phase 4
65 / 100
View asset →
cardiovascular disorderDormant
B
Indicative · Phase 3
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →